SCHEMBL6778090

SCHEMBL6778090

N#CN=C(NCc1cccnc1)Nc1cccc(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
NPC1 O15118 3/20 0.50
LMNA P02545 1/20 0.50
RAB9A P51151 4/20 0.49
KMT2A Q03164 2/20 0.49
MITF O75030 1/20 0.49
MAPK1 P28482 1/20 0.49
NAMPT P43490 2/20 0.47
TBXA2R P21731 3/20 0.47
TBXAS1 P24557 3/20 0.47
KMO O15229 1/20 0.46
EPHX1 P07099 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
PKM P14618 1/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778088 1.00 TSHR (0.57) TSHRSMN1; SMN2L3MBTL1NPC1LMNA
SCHEMBL6783215 0.89 TSHR (0.57) TSHRSMN1; SMN2L3MBTL1NPC1LMNA
SCHEMBL6783217 0.89 TSHR (0.57) TSHRSMN1; SMN2L3MBTL1NPC1LMNA
SCHEMBL9002910 0.83 TBXA2R (0.72) TBXA2RTBXAS1
SCHEMBL9002888 0.83 TBXA2R (0.72) TBXA2RTBXAS1
SCHEMBL9002896 0.83 TBXA2R (0.72) TBXA2RTBXAS1
SCHEMBL11157675 0.81 NAMPT (0.51) SMN1; SMN2L3MBTL1NPC1LMNARAB9A
SCHEMBL6778045 0.80 RAB9A (0.56) TSHRSMN1; SMN2L3MBTL1NPC1LMNA
SCHEMBL6778042 0.80 RAB9A (0.56) TSHRSMN1; SMN2L3MBTL1NPC1LMNA
SCHEMBL9002133 0.80 TBXA2R (0.72) TBXA2RTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed